Association of Circulating Tumor Cells with Inflammatory and Biomarkers in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer

Association of Circulating Tumor Cells with Inflammatory and Biomarkers in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer

The identification of specific biomarkers that recognize the functional drivers of heterogeneity in prostate cancer (PCa) and personalized treatment remain challenging in systemic medicine. Liquid biopsy allows for the detection and analysis of personalized predictive biomarkers in single blood samp...

Full description

Bibliographic Details
Main Authors:	Gerit Theil, Carlotta Lindner, Joanna Bialek, Paolo Fornara
Format:	Article
Language:	English
Published:	MDPI AG 2021-07-01
Series:	Life
Subjects:	biomarker circulating tumor cells prostate cancer
Online Access:	https://www.mdpi.com/2075-1729/11/7/664

Similar Items

Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients
by: Gerit Theil, et al.
Published: (2020-12-01)

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
by: Ingeborg E. de Kruijff, et al.
Published: (2019-08-01)

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
by: Rebeca Lozano, et al.
Published: (2021-05-01)

Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential
by: Marianne Trier Bjerre, et al.
Published: (2020-05-01)

Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy
by: Takatsugu Okegawa, et al.
Published: (2016-11-01)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
by: Edoardo Francini, et al.
Published: (2021-08-01)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
by: Vincenza Conteduca, et al.
Published: (2021-01-01)

Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance
by: Jiwoong Yu, et al.
Published: (2021-03-01)

Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Chun Wang, et al.
Published: (2021-01-01)

Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy
by: C. Hoey, et al.
Published: (2019-05-01)

Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
by: Magbanua Mark, et al.
Published: (2012-02-01)

Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer
by: David Lu, et al.
Published: (2020-10-01)

The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer
by: Alessio Crippa, et al.
Published: (2020-06-01)

Chemotherapy options in castration-resistant prostate cancer
by: Benjamin A Teply, et al.
Published: (2016-01-01)

Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients
by: Carlo Cattrini, et al.
Published: (2019-09-01)

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
by: Wout Devlies, et al.
Published: (2020-11-01)

Advances in Prognostic Methylation Biomarkers for Prostate Cancer
by: Dilys Lam, et al.
Published: (2020-10-01)

Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients
by: Weelic Chong, et al.
Published: (2021-06-01)

A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group
by: Brian D. Kelly, et al.
Published: (2015-07-01)

An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer
by: Helen Saxby, et al.
Published: (2020-07-01)

Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer
by: Sumiyoshi, Takayuki
Published: (2019)

Integrating Circulating Tumor Cell Data with Imaging and Serum Prostate-Specific Antigen Measurement for Metastatic Prostate Cancer Therapy Management
by: Oscar Goodman, et al.
Published: (2014-03-01)

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review
by: Shengri Tian, et al.
Published: (2020-08-01)

An expanded biomarker panel for the detection of prostate cancer from urine DNA
by: Igor Brikun, et al.
Published: (2019-06-01)

Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer
by: Itsuto Hamano, et al.
Published: (2020-07-01)

Post-Biopsy Cell-Free DNA From Blood: An Open Window on Primary Prostate Cancer Genetics and Biology
by: Marinella Corbetta, et al.
Published: (2021-05-01)

Current status of liquid biopsies for the detection and management of prostate cancer
by: Lu YT, et al.
Published: (2019-06-01)

When Prostate Cancer Circulates in the Bloodstream
by: Virginie Vlaeminck-Guillem
Published: (2015-10-01)

Folate-Receptor Positive Circulating Tumor Cell Is a Potential Diagnostic Marker of Prostate Cancer
by: Shenyi Lian, et al.
Published: (2021-10-01)

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer
by: Vincenzo Di Nunno, et al.
Published: (2018-09-01)

Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer
by: Michael Ladurner, et al.
Published: (2021-08-01)

Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction
by: David Bidarra, et al.
Published: (2019-09-01)

Circulating tumor cell count during zoledronic acid treatment in men with metastatic prostate cancer: a pilot study
by: Hisamitsu Ide, et al.
Published: (2014-09-01)

Transcription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer
by: Naoya Nagaya, et al.
Published: (2021-05-01)

Circulating MicroRNAs: Potential Biomarkers for Cancer
by: Yi-Tao Ding, et al.
Published: (2011-03-01)

Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients
by: Luis León-Mateos, et al.
Published: (2020-07-01)

Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer
by: Ingrid Jenny Guldvik, et al.
Published: (2021-06-01)

Characterizing glucocorticoid receptor in metastatic castration resistant prostate cancer
by: Kahn, Matthew Adam
Published: (2020)

Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians
by: Sanjoy Kumar Sureka, et al.
Published: (2016-01-01)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
by: Anieta M. Sieuwerts, et al.
Published: (2019-08-01)